N4#';[9>OQ=S')_KZTM7*OC2WE)7$
SYSTEM PROCESSING...
N4#';[9>OQ=S')_KZTM7*OC2WE)7$
SYSTEM PROCESSING...
Posted: 2025-04-25 22:06:50 UTC
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
Status
Last Updated
2025-04-25 22:38:30 UTC
Verified By
Rollup News
A phase 1 trial by Nieto et al. investigates the safety and preliminary efficacy of cord blood-derived, cytokine-pre-activated, and expanded NK cells pre-complexed with AFM13 in patients with refractory relapsed lymphoma.
Favorable safety profiles
Preliminary activity of NK cells
Use of AFM13 bispecific antibody
Treatment of refractory relapsed lymphoma
Refractory relapsed lymphoma treatment